Full-Time

Director – Clinical Design Physician

Cardiometabolic Health

Posted on 5/9/2026

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

No salary listed

Indianapolis, IN, USA

Hybrid

Willing to relocate to Indianapolis; remote work possible only in a hybrid environment if relocation is not possible.

Category
Medical, Clinical & Veterinary (1)
Required Skills
biostatistics
Requirements
  • Medical Doctor or Doctor of Osteopathy; must be board eligible or certified in appropriate specialty/subspecialty or have completed the comparable level of post-medical school clinical training relevant to the country of hiring
  • Pharmaceutical Industry experience of at least three years and adequate to provide strong grounding in the drug development process, clinical trial principles, and scientific decision-making
  • Experience of a minimum of three years in multiple areas relevant to clinical trial design (e.g., statistical/inferential methods, rating instruments, regulatory standards, safety assessment, investigator/site management, decentralized clinical trials)
  • U.S. trained physicians must have achieved board eligibility or certification; foreign medical graduates must have completed education and training at a medical school meeting LCME requirements; willingness to relocate to Indianapolis or work effectively from remote location in a hybrid environment if relocation is not possible
  • Willingness to travel domestically and internationally as needed to support the business of the team
Responsibilities
  • Translate therapeutic area and asset team strategy into clinical development program objectives and trial optionality as Medical leader on a cross-functional Clinical Design team; ensure optionality aligns with product lifecycle, business needs, patient, prescriber, payer and regulator considerations; articulate tradeoffs in information gathered, risks, cost, and time
  • Represent program and trial design optionality to asset teams and senior leaders to inform prioritization of options that will be translated into clinical protocols; adjust optionality based on leadership feedback
  • Develop study protocols in collaboration with the Design Team and Lilly Cardiometabolic Health Business Unit Development Team, Discovery, Program Phase Medicine, and Clinical Pharmacology; provide insight into impact of study design features on execution speed/efficiency
  • Contribute to asset strategy development (identifying target patient populations) in partnership with the asset team; contribute to global and business unit alignment of portfolio clinical strategy and asset-specific clinical plans
  • Collaborate with clinical research staff in the design and conduct of clinical trials (sample size, patient commitment, timelines, grants, governance interactions); champion decentralized trials and diversity/equity/inclusion initiatives; assess how design elements influence delivery and adoption of these initiatives
  • Review risk profiles to ensure appropriate communication of risk to study subjects
  • Participate in investigator identification and selection with Clinical Design and clinical teams; actively participate in subject recruitment, diversity, and retention efforts
  • Support seamless transition of protocols from design to execution
  • Knowledge of and compliance with local laws and global policies regarding data dissemination; establish collaborations with external experts, thought leaders, and professional societies; participate in dissemination and preparation of final reports and publications
  • Critically read and evaluate relevant medical literature; stay updated on medical developments in relevant therapeutic areas; engage with asset teams to understand patients, medical and payer communities and business strategy
  • Focus on organizational learning and best practices; collaborate to improve standard approaches; evolve Lilly standards, tools, and best practices; provide leadership for standardized processes, templates, and tools
Desired Qualifications
  • Clinical trial design leadership in at least one key in-scope development phase (proof of concept, dose ranging, registration, and/or phase 3b/4 studies)
  • Board certification or eligibility within a specialty directly relevant to comorbidities of Diabetes (e.g., cardiology, obesity medicine, nephrology, hepatology) is strongly preferred
  • Clinical research experience in one or more comorbidities of Diabetes
  • Strong understanding of relevant diabetes-related comorbidities—pathology, pathophysiology, unmet needs, and treatment standards
  • Strong interpersonal, organizational, and negotiation skills
  • Ability to influence others cross-functionally and within the function to advance business strategies and objectives
  • Excellent teamwork skills; fluent in English with strong communication (verbal and written)
  • Drug development experience spanning all core phases (concept through registration)
  • Understanding of how design elements translate into delivery; bias for simplifying and reducing burden and creating value through design
  • Strong communication skills across presentations, meetings, protocol/regulatory document creation; ability to engage with stakeholders (team leaders, Sr. Leader decision makers, medical and non-medical counterparts, thought leaders, investigators, regulators)
  • Bias for action; desire to influence a broad portfolio across phases through exceptional clinical plan optionality and study design
  • MBA or relevant business training in life sciences
  • Strong foundation in statistical science including Bayesian statistics applied to study design; ability to communicate with statisticians and translate concepts for design optionality and protocols
  • Willingness to engage in limited domestic and international travel as appropriate to support business
  • U.S. trained physicians must have board eligibility or certification; Non-U.S. trained physicians must meet LCME requirements; relocation to Indianapolis or remote work capability

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • Mounjaro generates $8.66B Q1 2026 sales, surpassing Keytruda as world's top drug.
  • International Mounjaro revenue surges to $4.4B in Q1 2026 from China's reimbursement list.
  • $21B LEAP district investment opens first genetic medicine facility on May 6, 2026.

What critics are saying

  • Novo Nordisk's CagriSema achieves 22.7% weight loss, eroding tirzepatide share in 6-12 months.
  • Compounding pharmacies divert 25% GLP-1 prescriptions, slashing $10B annual revenue now.
  • Pfizer's danuglipron oral Phase 3 data halves injectable dominance in 12-18 months.

What makes Lilly USA unique

  • Foundayo delivers 11% weight loss as once-daily oral GLP-1 pill approved April 1, 2026.
  • Lebanon API facility launches 2027 as largest U.S. site producing tirzepatide and orforglipron.
  • $2.25B Profluent Bio deal develops AI-driven kilobase-scale DNA editing for genetic diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Lilly USA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.